Brodalumab: Efficacy, safety, and survival in mid‐term (52 w…

Emerging

6
Citations
10
Refs
2022
Year
Search Works
Work Details
  • DOI 10.1111/ijd.16527
  • PMID https://pubmed.ncbi.nlm.nih.gov/36495585
  • OpenAlex ID W4311114418
  • Type Article
  • Language EN
  • Published 10 Dec 2022
  • Volume 62 (5)
  • Pages 700–706
  • Source International Journal of Dermatology
  • Publisher Wiley
  • FWCI 0.38
  • Countries 1
  • Institutions 8
  • Added 23 Dec 2022
  • Updated 29 Sep 2026
External Links
OpenAlex Record DOI Resolver PubMed
MENU
0

Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain

Article 2022 EN

INTRODUCTION: Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin-17 (IL-17) receptor A and blocks the biological activity of the proinflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer, and IL- 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the le…

6

Citations

10

References

7

Authors

0.38

FWCI

Citations by Year
Last 3 years
Topics
Keywords
UN Sustainable Development Goals
1 SDGs
Authors & Affiliations
7 authors
#AuthorInstitutionsORCID
1 Manuel Galán‐Gutiérrez Instituto Maimónides de Invest… (ES) Hospital Universitario Reina S… (ES)
2 Pilar Font Instituto Maimónides de Invest… (ES) University of Córdoba (ES)
3 Laura Padilla Hospital Universitario de Jere… (ES) —
4 Carlos Hernandez‐Montoya Hospital de Poniente (ES) —
5 Daniel Godoy Hospital Regional Universitari… (ES) —
6 José Carlos Armario Hita Hospital Universitario Puerto … (ES)
7 Ricardo Ruíz‐Villaverde Corresponding Instituto de Investigación Bio… (ES)
Related Works
10

Data: OpenAlex